Alkem Laboratories Ltd

Alkem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alkem Laboratories Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Sell. This change reflects evolving market perceptions and relative valuation improvements within the Pharmaceuticals & Biotechnology sector, offering investors a fresh perspective on the stock’s price attractiveness.

Alkem Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alkem Laboratories Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, and moving averages, signal a cautious outlook as the stock price declined by 3.29% on 2 Jun 2026, closing at ₹5,317 from the previous close of ₹5,497.80.

Alkem Laboratories Ltd has experienced a notable 10.22% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in open interest, coupled with a decline in share price and increased delivery volumes, suggests a complex interplay of investor positioning and potential directional bets in the pharmaceutical sector.

Alkem Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a recent upgrade in price action, the stock’s overall technical grade has been downgraded to Sell, signalling caution for investors amid mixed signals from MACD, RSI, moving averages, and other momentum oscillators.

Alkem Laboratories Ltd has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers with a 2.19% gain on 29 May 2026, supported by robust volume and rising investor participation, reflecting renewed bullish sentiment despite a recent downgrade in its Mojo Grade to Sell.

Alkem Laboratories Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap outperformed its sector peers with a 2.27% gain today, supported by robust volume and rising investor participation, reflecting renewed optimism despite a recent downgrade in its Mojo Grade to Sell.

Alkem Laboratories Ltd has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers, supported by robust volume and price action, as traders recalibrate their directional bets amid evolving market dynamics.

Alkem Laboratories Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers, supported by robust volume and positive price momentum, though its overall rating has recently been downgraded to Sell by MarketsMOJO.

Alkem Laboratories Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reported a shift to a negative financial trend in the quarter ended March 2026, with key performance indicators showing a mixed bag of growth and contraction. Despite a strong rise in profit before tax, the company faces challenges in operating profit margins and interest costs, prompting a downgrade in its Mojo Grade from Hold to Sell.

Alkem Laboratories Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The pharmaceutical major’s stock has outperformed its sector peers, supported by rising volumes and positive price action, suggesting renewed investor confidence despite a recent downgrade in its mojo rating.

Alkem Laboratories Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock has outperformed its sector peers, supported by strong volume and price action, prompting a reassessment of its near-term directional outlook.

Alkem Laboratories Ltd., a prominent Mumbai-based pharmaceutical company with operations across branded generics, APIs, and nutraceuticals, delivered a deeply troubling Q4 FY26 performance that has sparked investor concern. With a market capitalisation of ₹66,705.91 crores, the company reported consolidated net profit of ₹236.46 crores for the March 2026 quarter, representing a dramatic 62.82% quarter-on-quarter decline and a 22.69% year-on-year contraction. The stock has responded with volatility, currently trading at ₹5,579.05, up 2.33% on the day but reflecting underlying investor anxiety about the company's profitability trajectory.

The Sensex remained flat on 29 May 2026, while Alkem Laboratories Ltd surged 5.35%, outperforming its Pharmaceuticals & Biotechnology sector by over 5 percentage points. This notable single-session gain stands out as a stock-specific event, reflecting strength beyond the broader market's muted movement.

Alkem Laboratories Ltd has witnessed a notable 10.25% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a 1.52% gain in the stock price, outperforming its Pharmaceuticals & Biotechnology sector peers and reversing a three-day downward trend.